Synchron Launches Patient Registry for Stentrode Brain Computer Interface

Synchron, the brain-computer interface (BCI) company developing endovascular technology to restore functionality in patients with motor impairment, today announced the launch of a community-centered BCI registry to bring patients, carers and clinicians together to learn how BCI is being designed to provide benefit to people with limited mobility.

Synchron's BCI technology is designed to decipher the neural code of the brain and find new ways to restore motor intent to control digital devices. The Synchron BCI represents a novel approach to restoring functionality in patients with limited mobility. By leveraging the natural highways of the brain, an individual's blood vessels, the device is implanted in the brain without the need for invasive brain surgery.

"We are thrilled to launch our community-centered BCI registry," said Tom Oxley, CEO & Founder, Synchron. "There is a grass roots movement happening with BCI. We are creating an avenue for potential users and their physicians to engage and stay connected while we prepare for the next stage of clinical trials."

"BCI technology enables individuals with motor impairment to regain independence," said David Lacomis, M.D., principal investigator and Chief of the Neuromuscular Division at UPMC and Professor of Neurology and Pathology at the University of Pittsburgh. "By controlling digital devices through one's own thoughts, BCI offers a transformative path towards performing daily tasks with greater ease and efficiency. From communication to accessing essential services online, BCI technology represents a ground-breaking frontier for individuals and their families."

The Synchron BCI is implanted in the blood vessel on the surface of the motor cortex of the brain via the jugular vein, through a minimally-invasive endovascular procedure. Once implanted, it is designed to detect and wirelessly transmit motor intent out of the brain, intended to restore the capability for severely paralyzed patients to control personal devices with hands-free point-and-click.

For more information about the Synchron BCI and our registry, visit https://synchronbci.com.

About Synchron

Synchron is a neurotechnology company developing an endovascular brain-computer interface (BCI) designed to restore functionality in patients with severe paralysis. The clinical-stage company is developing a neuroprosthesis to restore motor signaling to control digital devices and autonomy for individuals with motor impairment. Synchron is headquartered in New York City. For more information, visit www.synchron.com. Follow us @synchroninc.